Tiotropium in the Treatment of the Patients With Chronic Obstructive Pulmonary Disease (COPD)

June 26, 2014 updated by: Boehringer Ingelheim

Drug Use Results Survey of Tiotropium Bromide

To collect post-marketing safety and effectiveness information on the use of Tiotropium Inhalation Capsules (18 μg) in patients with chronic obstructive pulmonary disease in daily clinical settings

Study Overview

Status

Completed

Conditions

Pulmonary Disease, Chronic Obstructive

Intervention / Treatment

Drug: Spiriva (tiotropium bromide) inhalation capsules

Study Type

Observational

Enrollment (Actual)

3588

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Japan
- - Abashiri, Japan
    - Boehringer Ingelheim Investigational Site
  - Aizubangemachi, Japan
    - Boehringer Ingelheim Investigational Site
  - Aizumisatomachi, Japan
    - Boehringer Ingelheim Investigational Site
  - Aizuwakamatsu, Japan
    - Boehringer Ingelheim Investigational Site
  - Akashi, Japan
    - Boehringer Ingelheim Investigational Site
  - Akita, Japan
    - Boehringer Ingelheim Investigational Site
  - Ako, Japan
    - Boehringer Ingelheim Investigational Site
  - Amagasaki, Japan
    - Boehringer Ingelheim Investigational Site
  - Amakusa, Japan
    - Boehringer Ingelheim Investigational Site
  - Amimachi, Japan
    - Boehringer Ingelheim Investigational Site
  - Anan, Japan
    - Boehringer Ingelheim Investigational Site
  - Anjo, Japan
    - Boehringer Ingelheim Investigational Site
  - Arakawamachi, Japan
    - Boehringer Ingelheim Investigational Site
  - Arao, Japan
    - Boehringer Ingelheim Investigational Site
  - Aritacho, Japan
    - Boehringer Ingelheim Investigational Site
  - Asahikawa, Japan
    - Boehringer Ingelheim Investigational Site
  - Ashikaga, Japan
    - Boehringer Ingelheim Investigational Site
  - Atami, Japan
    - Boehringer Ingelheim Investigational Site
  - Atsugi, Japan
    - Boehringer Ingelheim Investigational Site
  - Awa, Japan
    - Boehringer Ingelheim Investigational Site
  - Ayabe, Japan
    - Boehringer Ingelheim Investigational Site
  - Ayagawacho, Japan
    - Boehringer Ingelheim Investigational Site
  - Ayase, Japan
    - Boehringer Ingelheim Investigational Site
  - Beppu, Japan
    - Boehringer Ingelheim Investigational Site
  - Bibai, Japan
    - Boehringer Ingelheim Investigational Site
  - Bungoohno, Japan
    - Boehringer Ingelheim Investigational Site
  - Chiba, Japan
    - Boehringer Ingelheim Investigational Site
  - Chigasaki, Japan
    - Boehringer Ingelheim Investigational Site
  - Chikusei, Japan
    - Boehringer Ingelheim Investigational Site
  - Chikushino, Japan
    - Boehringer Ingelheim Investigational Site
  - Chitose, Japan
    - Boehringer Ingelheim Investigational Site
  - Date, Japan
    - Boehringer Ingelheim Investigational Site
  - Ebetsu, Japan
    - Boehringer Ingelheim Investigational Site
  - Echizen, Japan
    - Boehringer Ingelheim Investigational Site
  - Emukaecho, Japan
    - Boehringer Ingelheim Investigational Site
  - Engarucho, Japan
    - Boehringer Ingelheim Investigational Site
  - Fuchuu, Japan
    - Boehringer Ingelheim Investigational Site
  - Fuji, Japan
    - Boehringer Ingelheim Investigational Site
  - Fujiidera, Japan
    - Boehringer Ingelheim Investigational Site
  - Fujikawaguchiko, Japan
    - Boehringer Ingelheim Investigational Site
  - Fujinomiya, Japan
    - Boehringer Ingelheim Investigational Site
  - Fukagawa, Japan
    - Boehringer Ingelheim Investigational Site
  - Fukaya, Japan
    - Boehringer Ingelheim Investigational Site
  - Fukuchiyama, Japan
    - Boehringer Ingelheim Investigational Site
  - Fukui, Japan
    - Boehringer Ingelheim Investigational Site
  - Fukuoka, Japan
    - Boehringer Ingelheim Investigational Site
  - Fukuroi, Japan
    - Boehringer Ingelheim Investigational Site
  - Fukushima, Japan
    - Boehringer Ingelheim Investigational Site
  - Fukutsu, Japan
    - Boehringer Ingelheim Investigational Site
  - Fukuyama, Japan
    - Boehringer Ingelheim Investigational Site
  - Funabashi, Japan
    - Boehringer Ingelheim Investigational Site
  - Futabamachi, Japan
    - Boehringer Ingelheim Investigational Site
  - Geiseimura, Japan
    - Boehringer Ingelheim Investigational Site
  - Gifu, Japan
    - Boehringer Ingelheim Investigational Site
  - Ginowan, Japan
    - Boehringer Ingelheim Investigational Site
  - Gobo, Japan
    - Boehringer Ingelheim Investigational Site
  - Gosen, Japan
    - Boehringer Ingelheim Investigational Site
  - Gotenba, Japan
    - Boehringer Ingelheim Investigational Site
  - Gyouda, Japan
    - Boehringer Ingelheim Investigational Site
  - Habikino, Japan
    - Boehringer Ingelheim Investigational Site
  - Hachinohe, Japan
    - Boehringer Ingelheim Investigational Site
  - Hachirogatamachi, Japan
    - Boehringer Ingelheim Investigational Site
  - Hagi, Japan
    - Boehringer Ingelheim Investigational Site
  - Hakodate, Japan
    - Boehringer Ingelheim Investigational Site
  - Hakusan, Japan
    - Boehringer Ingelheim Investigational Site
  - Hamada, Japan
    - Boehringer Ingelheim Investigational Site
  - Hamamatsu, Japan
    - Boehringer Ingelheim Investigational Site
  - Handa, Japan
    - Boehringer Ingelheim Investigational Site
  - Hanyuu, Japan
    - Boehringer Ingelheim Investigational Site
  - Hatsukaichi, Japan
    - Boehringer Ingelheim Investigational Site
  - Hayashimacho, Japan
    - Boehringer Ingelheim Investigational Site
  - Higashihiroshima, Japan
    - Boehringer Ingelheim Investigational Site
  - Higashimatsushima, Japan
    - Boehringer Ingelheim Investigational Site
  - Higashiomi, Japan
    - Boehringer Ingelheim Investigational Site
  - Higashiosaka, Japan
    - Boehringer Ingelheim Investigational Site
  - Hikari, Japan
    - Boehringer Ingelheim Investigational Site
  - Himeji, Japan
    - Boehringer Ingelheim Investigational Site
  - Hirakata, Japan
    - Boehringer Ingelheim Investigational Site
  - Hiratsuka, Japan
    - Boehringer Ingelheim Investigational Site
  - Hirosaki, Japan
    - Boehringer Ingelheim Investigational Site
  - Hiroshima, Japan
    - Boehringer Ingelheim Investigational Site
  - Hita, Japan
    - Boehringer Ingelheim Investigational Site
  - Hitachi, Japan
    - Boehringer Ingelheim Investigational Site
  - Hitoyoshi, Japan
    - Boehringer Ingelheim Investigational Site
  - Hofu, Japan
    - Boehringer Ingelheim Investigational Site
  - Iamabari, Japan
    - Boehringer Ingelheim Investigational Site
  - Ibaraki, Japan
    - Boehringer Ingelheim Investigational Site
  - Ibarakimachi, Japan
    - Boehringer Ingelheim Investigational Site
  - Ibigawacho, Japan
    - Boehringer Ingelheim Investigational Site
  - Ibusuki, Japan
    - Boehringer Ingelheim Investigational Site
  - Ichihara, Japan
    - Boehringer Ingelheim Investigational Site
  - Ichinomiya, Japan
    - Boehringer Ingelheim Investigational Site
  - Ichinoseki, Japan
    - Boehringer Ingelheim Investigational Site
  - Iga, Japan
    - Boehringer Ingelheim Investigational Site
  - Iida, Japan
    - Boehringer Ingelheim Investigational Site
  - Iizuka, Japan
    - Boehringer Ingelheim Investigational Site
  - Ikoma, Japan
    - Boehringer Ingelheim Investigational Site
  - Imari, Japan
    - Boehringer Ingelheim Investigational Site
  - Imizu, Japan
    - Boehringer Ingelheim Investigational Site
  - Ina, Japan
    - Boehringer Ingelheim Investigational Site
  - Inazawa, Japan
    - Boehringer Ingelheim Investigational Site
  - Inuyama, Japan
    - Boehringer Ingelheim Investigational Site
  - Isahaya, Japan
    - Boehringer Ingelheim Investigational Site
  - Ise, Japan
    - Boehringer Ingelheim Investigational Site
  - Isehara, Japan
    - Boehringer Ingelheim Investigational Site
  - Ishikari, Japan
    - Boehringer Ingelheim Investigational Site
  - Ishinomaki, Japan
    - Boehringer Ingelheim Investigational Site
  - Itami, Japan
    - Boehringer Ingelheim Investigational Site
  - Itanocho, Japan
    - Boehringer Ingelheim Investigational Site
  - Ito, Japan
    - Boehringer Ingelheim Investigational Site
  - Iwaki, Japan
    - Boehringer Ingelheim Investigational Site
  - Iwakuni, Japan
    - Boehringer Ingelheim Investigational Site
  - Iwamizawa, Japan
    - Boehringer Ingelheim Investigational Site
  - Iwanaicho, Japan
    - Boehringer Ingelheim Investigational Site
  - Iwata, Japan
    - Boehringer Ingelheim Investigational Site
  - Iyo, Japan
    - Boehringer Ingelheim Investigational Site
  - Izu, Japan
    - Boehringer Ingelheim Investigational Site
  - Izumisano, Japan
    - Boehringer Ingelheim Investigational Site
  - Izumo, Japan
    - Boehringer Ingelheim Investigational Site
  - Izunokuni, Japan
    - Boehringer Ingelheim Investigational Site
  - Jimokujicho, Japan
    - Boehringer Ingelheim Investigational Site
  - Joso, Japan
    - Boehringer Ingelheim Investigational Site
  - Jouetsu, Japan
    - Boehringer Ingelheim Investigational Site
  - Joyo, Japan
    - Boehringer Ingelheim Investigational Site
  - Kaga, Japan
    - Boehringer Ingelheim Investigational Site
  - Kagoshima, Japan
    - Boehringer Ingelheim Investigational Site
  - Kaizuka, Japan
    - Boehringer Ingelheim Investigational Site
  - Kajikicho, Japan
    - Boehringer Ingelheim Investigational Site
  - Kakegawa, Japan
    - Boehringer Ingelheim Investigational Site
  - Kami, Japan
    - Boehringer Ingelheim Investigational Site
  - Kamiamakusa, Japan
    - Boehringer Ingelheim Investigational Site
  - Kamisu, Japan
    - Boehringer Ingelheim Investigational Site
  - Kanazawa, Japan
    - Boehringer Ingelheim Investigational Site
  - Kandamachi, Japan
    - Boehringer Ingelheim Investigational Site
  - Kanonji, Japan
    - Boehringer Ingelheim Investigational Site
  - Kasai, Japan
    - Boehringer Ingelheim Investigational Site
  - Kasama, Japan
    - Boehringer Ingelheim Investigational Site
  - Kasaoka, Japan
    - Boehringer Ingelheim Investigational Site
  - Kashihara, Japan
    - Boehringer Ingelheim Investigational Site
  - Kashima, Japan
    - Boehringer Ingelheim Investigational Site
  - Kashiwazaki, Japan
    - Boehringer Ingelheim Investigational Site
  - Kasuga, Japan
    - Boehringer Ingelheim Investigational Site
  - Kasuigai, Japan
    - Boehringer Ingelheim Investigational Site
  - Kasukabe, Japan
    - Boehringer Ingelheim Investigational Site
  - Kasuyamachi, Japan
    - Boehringer Ingelheim Investigational Site
  - Kato, Japan
    - Boehringer Ingelheim Investigational Site
  - Katsuyama, Japan
    - Boehringer Ingelheim Investigational Site
  - Kawachinagano, Japan
    - Boehringer Ingelheim Investigational Site
  - Kawagoe, Japan
    - Boehringer Ingelheim Investigational Site
  - Kawaguchi, Japan
    - Boehringer Ingelheim Investigational Site
  - Kawanishimachi, Japan
    - Boehringer Ingelheim Investigational Site
  - Kawasaki, Japan
    - Boehringer Ingelheim Investigational Site
  - Kayano, Japan
    - Boehringer Ingelheim Investigational Site
  - Kazuno, Japan
    - Boehringer Ingelheim Investigational Site
  - Kinkocho, Japan
    - Boehringer Ingelheim Investigational Site
  - Kitakami, Japan
    - Boehringer Ingelheim Investigational Site
  - Kitakyushu, Japan
    - Boehringer Ingelheim Investigational Site
  - Kitami, Japan
    - Boehringer Ingelheim Investigational Site
  - Kobe, Japan
    - Boehringer Ingelheim Investigational Site
  - Kochi, Japan
    - Boehringer Ingelheim Investigational Site
  - Koga, Japan
    - Boehringer Ingelheim Investigational Site
  - Komonocho, Japan
    - Boehringer Ingelheim Investigational Site
  - Konan, Japan
    - Boehringer Ingelheim Investigational Site
  - Koriyama, Japan
    - Boehringer Ingelheim Investigational Site
  - Kouriyama, Japan
    - Boehringer Ingelheim Investigational Site
  - Koushi, Japan
    - Boehringer Ingelheim Investigational Site
  - Koushu, Japan
    - Boehringer Ingelheim Investigational Site
  - Kozakaicho, Japan
    - Boehringer Ingelheim Investigational Site
  - Kudamatsu, Japan
    - Boehringer Ingelheim Investigational Site
  - Kumamoto, Japan
    - Boehringer Ingelheim Investigational Site
  - Kunimimachi, Japan
    - Boehringer Ingelheim Investigational Site
  - Kunisaki, Japan
    - Boehringer Ingelheim Investigational Site
  - Kurashiki, Japan
    - Boehringer Ingelheim Investigational Site
  - Kurayoshi, Japan
    - Boehringer Ingelheim Investigational Site
  - Kure, Japan
    - Boehringer Ingelheim Investigational Site
  - Kurihara, Japan
    - Boehringer Ingelheim Investigational Site
  - Kurume, Japan
    - Boehringer Ingelheim Investigational Site
  - Kushiro, Japan
    - Boehringer Ingelheim Investigational Site
  - Kuwana, Japan
    - Boehringer Ingelheim Investigational Site
  - Kyotango, Japan
    - Boehringer Ingelheim Investigational Site
  - Kyoto, Japan
    - Boehringer Ingelheim Investigational Site
  - Maebashi, Japan
    - Boehringer Ingelheim Investigational Site
  - Marugame, Japan
    - Boehringer Ingelheim Investigational Site
  - Masuda, Japan
    - Boehringer Ingelheim Investigational Site
  - Matsudo, Japan
    - Boehringer Ingelheim Investigational Site
  - Matsue, Japan
    - Boehringer Ingelheim Investigational Site
  - Matsumoto, Japan
    - Boehringer Ingelheim Investigational Site
  - Matsusaka, Japan
    - Boehringer Ingelheim Investigational Site
  - Matsuyama, Japan
    - Boehringer Ingelheim Investigational Site
  - Mibumachi, Japan
    - Boehringer Ingelheim Investigational Site
  - Mihamacho, Japan
    - Boehringer Ingelheim Investigational Site
  - Mihara, Japan
    - Boehringer Ingelheim Investigational Site
  - Minamisatsuma, Japan
    - Boehringer Ingelheim Investigational Site
  - Minamisouma, Japan
    - Boehringer Ingelheim Investigational Site
  - Minamiuonuma, Japan
    - Boehringer Ingelheim Investigational Site
  - Mino, Japan
    - Boehringer Ingelheim Investigational Site
  - Minoh, Japan
    - Boehringer Ingelheim Investigational Site
  - Misasacho, Japan
    - Boehringer Ingelheim Investigational Site
  - Misato, Japan
    - Boehringer Ingelheim Investigational Site
  - Mishima, Japan
    - Boehringer Ingelheim Investigational Site
  - Mito, Japan
    - Boehringer Ingelheim Investigational Site
  - Miyakicho, Japan
    - Boehringer Ingelheim Investigational Site
  - Miyakonojo, Japan
    - Boehringer Ingelheim Investigational Site
  - Miyazaki, Japan
    - Boehringer Ingelheim Investigational Site
  - Miyoshi, Japan
    - Boehringer Ingelheim Investigational Site
  - Mizunami, Japan
    - Boehringer Ingelheim Investigational Site
  - Mobara, Japan
    - Boehringer Ingelheim Investigational Site
  - Moriguchi, Japan
    - Boehringer Ingelheim Investigational Site
  - Morioka, Japan
    - Boehringer Ingelheim Investigational Site
  - Muroran, Japan
    - Boehringer Ingelheim Investigational Site
  - Nabari, Japan
    - Boehringer Ingelheim Investigational Site
  - Nagahama, Japan
    - Boehringer Ingelheim Investigational Site
  - Nagano, Japan
    - Boehringer Ingelheim Investigational Site
  - Nagaoka, Japan
    - Boehringer Ingelheim Investigational Site
  - Nagasaki, Japan
    - Boehringer Ingelheim Investigational Site
  - Nagato, Japan
    - Boehringer Ingelheim Investigational Site
  - Nago, Japan
    - Boehringer Ingelheim Investigational Site
  - Nagoya, Japan
    - Boehringer Ingelheim Investigational Site
  - Naha, Japan
    - Boehringer Ingelheim Investigational Site
  - Nakama, Japan
    - Boehringer Ingelheim Investigational Site
  - Nakashibetsucho, Japan
    - Boehringer Ingelheim Investigational Site
  - Nanao, Japan
    - Boehringer Ingelheim Investigational Site
  - Nankoku, Japan
    - Boehringer Ingelheim Investigational Site
  - Nantan, Japan
    - Boehringer Ingelheim Investigational Site
  - Nara, Japan
    - Boehringer Ingelheim Investigational Site
  - Naruto, Japan
    - Boehringer Ingelheim Investigational Site
  - Nasukarasuyama, Japan
    - Boehringer Ingelheim Investigational Site
  - Neyagawa, Japan
    - Boehringer Ingelheim Investigational Site
  - Nihonmatsu, Japan
    - Boehringer Ingelheim Investigational Site
  - Niigata, Japan
    - Boehringer Ingelheim Investigational Site
  - Niihamashi, Japan
    - Boehringer Ingelheim Investigational Site
  - Nikko, Japan
    - Boehringer Ingelheim Investigational Site
  - Nishiiyo, Japan
    - Boehringer Ingelheim Investigational Site
  - Nishinomiya, Japan
    - Boehringer Ingelheim Investigational Site
  - Nishio, Japan
    - Boehringer Ingelheim Investigational Site
  - Nobeoka, Japan
    - Boehringer Ingelheim Investigational Site
  - Noboribetsu, Japan
    - Boehringer Ingelheim Investigational Site
  - Noda, Japan
    - Boehringer Ingelheim Investigational Site
  - Nomi, Japan
    - Boehringer Ingelheim Investigational Site
  - Noshiro, Japan
    - Boehringer Ingelheim Investigational Site
  - Notocho, Japan
    - Boehringer Ingelheim Investigational Site
  - Numata, Japan
    - Boehringer Ingelheim Investigational Site
  - Numazu, Japan
    - Boehringer Ingelheim Investigational Site
  - Oaraimachi, Japan
    - Boehringer Ingelheim Investigational Site
  - Obama, Japan
    - Boehringer Ingelheim Investigational Site
  - Obihiro, Japan
    - Boehringer Ingelheim Investigational Site
  - Odate, Japan
    - Boehringer Ingelheim Investigational Site
  - Odawara, Japan
    - Boehringer Ingelheim Investigational Site
  - Ogawaramachi, Japan
    - Boehringer Ingelheim Investigational Site
  - Ogi, Japan
    - Boehringer Ingelheim Investigational Site
  - Oita, Japan
    - Boehringer Ingelheim Investigational Site
  - Ojiya, Japan
    - Boehringer Ingelheim Investigational Site
  - Okayama, Japan
    - Boehringer Ingelheim Investigational Site
  - Okinawa, Japan
    - Boehringer Ingelheim Investigational Site
  - Omihachiman, Japan
    - Boehringer Ingelheim Investigational Site
  - Omuta, Japan
    - Boehringer Ingelheim Investigational Site
  - Onomachi, Japan
    - Boehringer Ingelheim Investigational Site
  - Osaka, Japan
    - Boehringer Ingelheim Investigational Site
  - Osakasayama, Japan
    - Boehringer Ingelheim Investigational Site
  - Ota, Japan
    - Boehringer Ingelheim Investigational Site
  - Otake, Japan
    - Boehringer Ingelheim Investigational Site
  - Otaru, Japan
    - Boehringer Ingelheim Investigational Site
  - Otsu, Japan
    - Boehringer Ingelheim Investigational Site
  - Otsumachi, Japan
    - Boehringer Ingelheim Investigational Site
  - Owariasahi, Japan
    - Boehringer Ingelheim Investigational Site
  - Ritto, Japan
    - Boehringer Ingelheim Investigational Site
  - Ryugasaki, Japan
    - Boehringer Ingelheim Investigational Site
  - Sado, Japan
    - Boehringer Ingelheim Investigational Site
  - Saga, Japan
    - Boehringer Ingelheim Investigational Site
  - Sagamihara, Japan
    - Boehringer Ingelheim Investigational Site
  - Saiki, Japan
    - Boehringer Ingelheim Investigational Site
  - Saitama, Japan
    - Boehringer Ingelheim Investigational Site
  - Sakacho, Japan
    - Boehringer Ingelheim Investigational Site
  - Sakai, Japan
    - Boehringer Ingelheim Investigational Site
  - Sakaimachi, Japan
    - Boehringer Ingelheim Investigational Site
  - Sakaiminato, Japan
    - Boehringer Ingelheim Investigational Site
  - Sakata, Japan
    - Boehringer Ingelheim Investigational Site
  - Saku, Japan
    - Boehringer Ingelheim Investigational Site
  - Sanjyo, Japan
    - Boehringer Ingelheim Investigational Site
  - Sanuki, Japan
    - Boehringer Ingelheim Investigational Site
  - Sanyoonoda, Japan
    - Boehringer Ingelheim Investigational Site
  - Sapporo, Japan
    - Boehringer Ingelheim Investigational Site
  - Sasayama, Japan
    - Boehringer Ingelheim Investigational Site
  - Sasebo, Japan
    - Boehringer Ingelheim Investigational Site
  - Satsumasendai, Japan
    - Boehringer Ingelheim Investigational Site
  - Sayama, Japan
    - Boehringer Ingelheim Investigational Site
  - Sendai, Japan
    - Boehringer Ingelheim Investigational Site
  - Sennan, Japan
    - Boehringer Ingelheim Investigational Site
  - Shibetsu, Japan
    - Boehringer Ingelheim Investigational Site
  - Shibukawa, Japan
    - Boehringer Ingelheim Investigational Site
  - Shimada, Japan
    - Boehringer Ingelheim Investigational Site
  - Shimonoseki, Japan
    - Boehringer Ingelheim Investigational Site
  - Shimotsuke, Japan
    - Boehringer Ingelheim Investigational Site
  - Shimotsuma, Japan
    - Boehringer Ingelheim Investigational Site
  - Shingu, Japan
    - Boehringer Ingelheim Investigational Site
  - Shiogama, Japan
    - Boehringer Ingelheim Investigational Site
  - Shirahamacho, Japan
    - Boehringer Ingelheim Investigational Site
  - Shiroishi, Japan
    - Boehringer Ingelheim Investigational Site
  - Shiroishicho, Japan
    - Boehringer Ingelheim Investigational Site
  - Shizuoka, Japan
    - Boehringer Ingelheim Investigational Site
  - Shoocho, Japan
    - Boehringer Ingelheim Investigational Site
  - Shunan, Japan
    - Boehringer Ingelheim Investigational Site
  - Soo, Japan
    - Boehringer Ingelheim Investigational Site
  - Souka, Japan
    - Boehringer Ingelheim Investigational Site
  - Suita, Japan
    - Boehringer Ingelheim Investigational Site
  - Sukagawa, Japan
    - Boehringer Ingelheim Investigational Site
  - Sukumo, Japan
    - Boehringer Ingelheim Investigational Site
  - Sunagawa, Japan
    - Boehringer Ingelheim Investigational Site
  - Susono, Japan
    - Boehringer Ingelheim Investigational Site
  - Suwa, Japan
    - Boehringer Ingelheim Investigational Site
  - Suzuka, Japan
    - Boehringer Ingelheim Investigational Site
  - Tagawa, Japan
    - Boehringer Ingelheim Investigational Site
  - Tainai, Japan
    - Boehringer Ingelheim Investigational Site
  - Takahashi, Japan
    - Boehringer Ingelheim Investigational Site
  - Takamatsu, Japan
    - Boehringer Ingelheim Investigational Site
  - Takaoka, Japan
    - Boehringer Ingelheim Investigational Site
  - Takarazuka, Japan
    - Boehringer Ingelheim Investigational Site
  - Takasago, Japan
    - Boehringer Ingelheim Investigational Site
  - Takashima, Japan
    - Boehringer Ingelheim Investigational Site
  - Takatsuki, Japan
    - Boehringer Ingelheim Investigational Site
  - Taku, Japan
    - Boehringer Ingelheim Investigational Site
  - Tamana, Japan
    - Boehringer Ingelheim Investigational Site
  - Tamano, Japan
    - Boehringer Ingelheim Investigational Site
  - Tanabe, Japan
    - Boehringer Ingelheim Investigational Site
  - Taragimachi, Japan
    - Boehringer Ingelheim Investigational Site
  - Tenri, Japan
    - Boehringer Ingelheim Investigational Site
  - Tokaimura, Japan
    - Boehringer Ingelheim Investigational Site
  - Tokamachi, Japan
    - Boehringer Ingelheim Investigational Site
  - Tokorozawa, Japan
    - Boehringer Ingelheim Investigational Site
  - Tokunoshimacho, Japan
    - Boehringer Ingelheim Investigational Site
  - Tokushima, Japan
    - Boehringer Ingelheim Investigational Site
  - Tokyo Adachi-ku, Japan
    - Boehringer Ingelheim Investigational Site
  - Tokyo Akishima, Japan
    - Boehringer Ingelheim Investigational Site
  - Tokyo Bunkyo-ku, Japan
    - Boehringer Ingelheim Investigational Site
  - Tokyo Chiyoda-ku, Japan
    - Boehringer Ingelheim Investigational Site
  - Tokyo Edogawa-ku, Japan
    - Boehringer Ingelheim Investigational Site
  - Tokyo Hachioji, Japan
    - Boehringer Ingelheim Investigational Site
  - Tokyo Higashimurayama, Japan
    - Boehringer Ingelheim Investigational Site
  - Tokyo Higashiyamato, Japan
    - Boehringer Ingelheim Investigational Site
  - Tokyo Hino, Japan
    - Boehringer Ingelheim Investigational Site
  - Tokyo Itabashi-ku, Japan
    - Boehringer Ingelheim Investigational Site
  - Tokyo Katsushika-ku, Japan
    - Boehringer Ingelheim Investigational Site
  - Tokyo Kiyose, Japan
    - Boehringer Ingelheim Investigational Site
  - Tokyo Komae, Japan
    - Boehringer Ingelheim Investigational Site
  - Tokyo Koto-ku, Japan
    - Boehringer Ingelheim Investigational Site
  - Tokyo Meguro-ku, Japan
    - Boehringer Ingelheim Investigational Site
  - Tokyo Minato-ku, Japan
    - Boehringer Ingelheim Investigational Site
  - Tokyo Nakano-ku, Japan
    - Boehringer Ingelheim Investigational Site
  - Tokyo Nerima-ku, Japan
    - Boehringer Ingelheim Investigational Site
  - Tokyo Nishitokyo, Japan
    - Boehringer Ingelheim Investigational Site
  - Tokyo Ome, Japan
    - Boehringer Ingelheim Investigational Site
  - Tokyo Ota-ku, Japan
    - Boehringer Ingelheim Investigational Site
  - Tokyo Setagaya-ku, Japan
    - Boehringer Ingelheim Investigational Site
  - Tokyo Shibuya-ku, Japan
    - Boehringer Ingelheim Investigational Site
  - Tokyo Shinagawa-ku, Japan
    - Boehringer Ingelheim Investigational Site
  - Tokyo Shinjuku-ku, Japan
    - Boehringer Ingelheim Investigational Site
  - Tokyo Suginami-ku, Japan
    - Boehringer Ingelheim Investigational Site
  - Tokyo Sumida-ku, Japan
    - Boehringer Ingelheim Investigational Site
  - Tokyo Taito-ku, Japan
    - Boehringer Ingelheim Investigational Site
  - Tokyo Toshima-ku, Japan
    - Boehringer Ingelheim Investigational Site
  - Tomakomai, Japan
    - Boehringer Ingelheim Investigational Site
  - Tomigusu, Japan
    - Boehringer Ingelheim Investigational Site
  - Tomioka, Japan
    - Boehringer Ingelheim Investigational Site
  - Tondabayashi, Japan
    - Boehringer Ingelheim Investigational Site
  - Toride, Japan
    - Boehringer Ingelheim Investigational Site
  - Tottori, Japan
    - Boehringer Ingelheim Investigational Site
  - Toyama, Japan
    - Boehringer Ingelheim Investigational Site
  - Toyohashi, Japan
    - Boehringer Ingelheim Investigational Site
  - Toyokawa, Japan
    - Boehringer Ingelheim Investigational Site
  - Toyooka, Japan
    - Boehringer Ingelheim Investigational Site
  - Toyosatocho, Japan
    - Boehringer Ingelheim Investigational Site
  - Toyota, Japan
    - Boehringer Ingelheim Investigational Site
  - Tsu, Japan
    - Boehringer Ingelheim Investigational Site
  - Tsukuba, Japan
    - Boehringer Ingelheim Investigational Site
  - Tsurugicho, Japan
    - Boehringer Ingelheim Investigational Site
  - Tsuruoka, Japan
    - Boehringer Ingelheim Investigational Site
  - Tsushima, Japan
    - Boehringer Ingelheim Investigational Site
  - Tsuyama, Japan
    - Boehringer Ingelheim Investigational Site
  - Ube, Japan
    - Boehringer Ingelheim Investigational Site
  - Uchikocho, Japan
    - Boehringer Ingelheim Investigational Site
  - Uchinadamachi, Japan
    - Boehringer Ingelheim Investigational Site
  - Uekimachi, Japan
    - Boehringer Ingelheim Investigational Site
  - Uji, Japan
    - Boehringer Ingelheim Investigational Site
  - Uki, Japan
    - Boehringer Ingelheim Investigational Site
  - Unzen, Japan
    - Boehringer Ingelheim Investigational Site
  - Urakawacho, Japan
    - Boehringer Ingelheim Investigational Site
  - Urasoe, Japan
    - Boehringer Ingelheim Investigational Site
  - Urayasu, Japan
    - Boehringer Ingelheim Investigational Site
  - Uruma, Japan
    - Boehringer Ingelheim Investigational Site
  - Usa, Japan
    - Boehringer Ingelheim Investigational Site
  - Usuki, Japan
    - Boehringer Ingelheim Investigational Site
  - Utsunomiya, Japan
    - Boehringer Ingelheim Investigational Site
  - Wakayama, Japan
    - Boehringer Ingelheim Investigational Site
  - Yabu, Japan
    - Boehringer Ingelheim Investigational Site
  - Yachimata, Japan
    - Boehringer Ingelheim Investigational Site
  - Yachiyo, Japan
    - Boehringer Ingelheim Investigational Site
  - Yaizu, Japan
    - Boehringer Ingelheim Investigational Site
  - Yakumocho, Japan
    - Boehringer Ingelheim Investigational Site
  - Yakushimacho, Japan
    - Boehringer Ingelheim Investigational Site
  - Yamaga, Japan
    - Boehringer Ingelheim Investigational Site
  - Yamagata, Japan
    - Boehringer Ingelheim Investigational Site
  - Yamato, Japan
    - Boehringer Ingelheim Investigational Site
  - Yamatotakada, Japan
    - Boehringer Ingelheim Investigational Site
  - Yanai, Japan
    - Boehringer Ingelheim Investigational Site
  - Yao, Japan
    - Boehringer Ingelheim Investigational Site
  - Yatomi, Japan
    - Boehringer Ingelheim Investigational Site
  - Yatsushiro, Japan
    - Boehringer Ingelheim Investigational Site
  - Yawata, Japan
    - Boehringer Ingelheim Investigational Site
  - Yokkaichi, Japan
    - Boehringer Ingelheim Investigational Site
  - Yokohama, Japan
    - Boehringer Ingelheim Investigational Site
  - Yokosuka, Japan
    - Boehringer Ingelheim Investigational Site
  - Yokote, Japan
    - Boehringer Ingelheim Investigational Site
  - Yonabarucho, Japan
    - Boehringer Ingelheim Investigational Site
  - Yonezawa, Japan
    - Boehringer Ingelheim Investigational Site
  - Yorocho, Japan
    - Boehringer Ingelheim Investigational Site
  - Yoshinocho, Japan
    - Boehringer Ingelheim Investigational Site
  - Yufu, Japan
    - Boehringer Ingelheim Investigational Site
  - Yurihonjou, Japan
    - Boehringer Ingelheim Investigational Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

Child
Adult
Older Adult

Accepts Healthy Volunteers

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

COPD patients in daily clinical settings.

Description

Inclusion Criteria:

- Patients with COPD

Exclusion Criteria:

-There is no exclusion criterion, because this post marketing study (PMS) is observational survey under condition of normal clinical practice

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Number of groups / cohorts

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Patients with COPD	Drug: Spiriva (tiotropium bromide) inhalation capsules Survey of patients with COPD using Spiriva (tiotropium bromide) inhalation capsules

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Number of patients with adverse events Time Frame: Up to 4 weeks after start of treatment	Up to 4 weeks after start of treatment
Number of patients with adverse drug reactions Time Frame: Up to 4 weeks after start of treatment	Up to 4 weeks after start of treatment
Number of patients with serious adverse events Time Frame: Up to 4 weeks after start of treatment	Up to 4 weeks after start of treatment

Secondary Outcome Measures

Outcome Measure	Time Frame
Physician's overall judgement by medical interview into four grades: 1. Improved 2. No Change 3. Aggravated 4.Unassessable Time Frame: Up to 4 weeks after start of treatment	Up to 4 weeks after start of treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Boehringer Ingelheim

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

April 1, 2005

Primary Completion (Actual)

September 1, 2007

Study Registration Dates

First Submitted

January 31, 2008

First Submitted That Met QC Criteria

June 26, 2014

First Posted (Estimate)

June 27, 2014

Study Record Updates

Last Update Posted (Estimate)

June 27, 2014

Last Update Submitted That Met QC Criteria

June 26, 2014

Last Verified

June 1, 2014

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

205.314

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pulmonary Disease, Chronic Obstructive

Spire, Inc.
ResMed

Completed

An Exploratory, Observational, Non-interventional, Open Label, Remote Pilot Study to Assess Adherence in COPD Subjects

Severe Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary Disease

United States
University of Leicester
University Hospitals, Leicester; University of Strathclyde

Recruiting

Make Every Step Count: Personalised Music Feedback to Walking for People Living With COPD (MuSiC)

Chronic Obstructive Pulmonary Disease (COPD) | Chronic Obstructive Lung Disease | Chronic Obstructive Airway Disease

United Kingdom
National Taipei University of Nursing and Health...

Terminated

Bubble PEP Training Among Patient With Chronic Obstructive Pulmonary Disease in Pulmonary Function Effects

Chronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With Exacerbation

Taiwan
Karaganda Medical University

Completed

Association of Cathelicidin and Vitamin D Levels With the Category and Course of COPD (COPD)

Chronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease Moderate | Chronic Obstructive Pulmonary Disease Severe

Kazakhstan
Randall Debattista
University of Malta, Faculty of Health Sciences

Not yet recruiting

Effect of NMES on Quadriceps Muscle Strength and Endurance in Patients With COPD (NMES)

Chronic Obstructive Pulmonary Disease Moderate | Acute Exacerbation of COPD | Chronic Obstructive Pulmonary Disease Severe
Cukurova University

Completed

Effect Of Ketamine Infusion In Patients With COPD Applied One Lung Ventilation

Anesthesia | Chronic Obstructive Pulmonary Disease Moderate | Lungcancer | Chronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease Mild

Turkey
Taipei Medical University

Unknown

Effects of a Comprehensive Health Coaching Program in Advanced Chronic Obstructive Pulmonary Disease.

Chronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease End Stage

Taiwan
Hopital Foch
Air Liquide SA

Recruiting

Exploration of the VOLATOLOM in the Stable Severe COPD (Chronic Obstructive Pulmonary Disease) (VOC-BPCO)

Chronic Obstructive Pulmonary Disease Severe

France
Fundación para la Investigación del Hospital Clínico...

Not yet recruiting

GOLD 0 - DLCO 1: A Look Beyond the Obstruction. Is Spirometry Enough for COPD (Chronic Obstructive Pulmonary Disease) Screening?

COPD, Chronic Obstructive Pulmonary Disease

Spain
Canandaigua VA Medical Center

Recruiting

Manual Therapy in Addition to Pulmonary Rehabilitation in Moderate Chronic Obstructive Pulmonary Disease.

Chronic Obstructive Pulmonary Disease Moderate

United States

Clinical Trials on Spiriva (tiotropium bromide) inhalation capsules

Duke University

Withdrawn

Tiotropium Handihaler vs. Tiotropium Respimat in COPD

Chronic Obstructive Pulmonary Disease (COPD)
Orion Corporation, Orion Pharma

Completed

Inspiratory Flow Parameters With Placebo Easyhaler and Placebo HandiHaler (TIOPIF)

Healthy Volunteer | COPD

Estonia
Chia Tai Tianqing Pharmaceutical (Guangzhou) Co...

Recruiting

A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TQC3302 Inhalation Spray in Healthy Adult Subjects

Chronic Obstructive Pulmonary Disease

China
Xiromed LLC
Laboratorios Liconsa; Exeltis

Completed

Bioequivalence Study of Tiotropium 18 μg Inhalation Powder, Hard Capsule With Spiriva®Handihaler® 18 μg Inhalation Powder, Hard Capsule in Patients With Chronic Obstructive Pulmonary Disease (COPD) (ARBORUS)

COPD

United States, India
Glenmark Specialty S.A.

Completed

Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Inhalation Solution in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)

United States
Boehringer Ingelheim

Completed

Effect of Tiotropium on Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
Orion Corporation, Orion Pharma

Completed

Comparison of Tiotropium Absorption From Tiotropium Easyhaler and Spiriva HandiHaler (TEMPO)

Healthy Volunteers

Finland
Boehringer Ingelheim

Completed

Efficacy and Safety of Tiotropium in Patients With COPD and Concomitant Diagnosis of Asthma

Pulmonary Disease, Chronic Obstructive | Asthma

Netherlands, Germany, Belgium, France, Canada, Italy, South Africa, Denmark
Boehringer Ingelheim

Completed

12-week Treatment With Inhaled Tiotropium (18 mcg Once Daily) on Lung Function and Static Lung Volumes in Stable, Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Patients. Correlation to Dyspnoea Scales

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Completed

Comparison of Tiotropium Inhalation Capsules and Atrovent Metered Dose Inhaler (MDI) in a Efficacy and Safety Study in Adults With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Tiotropium in the Treatment of the Patients With Chronic Obstructive Pulmonary Disease (COPD)

Drug Use Results Survey of Tiotropium Bromide

Study Overview

Status

Conditions

Intervention / Treatment

Study Type

Enrollment (Actual)

Contacts and Locations

Study Locations

Participation Criteria

Eligibility Criteria

Ages Eligible for Study

Accepts Healthy Volunteers

Genders Eligible for Study

Sampling Method

Study Population

Description

Study Plan

How is the study designed?

Design Details

Number of groups / cohorts

Cohorts and Interventions

Group / Cohort

Intervention / Treatment

What is the study measuring?

Primary Outcome Measures

Outcome Measure

Time Frame

Secondary Outcome Measures

Outcome Measure

Time Frame

Collaborators and Investigators

Sponsor

Study record dates

Study Major Dates

Study Start

Primary Completion (Actual)

Study Registration Dates

First Submitted

First Submitted That Met QC Criteria

First Posted (Estimate)

Study Record Updates

Last Update Posted (Estimate)

Last Update Submitted That Met QC Criteria

Last Verified

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Clinical Trials on Pulmonary Disease, Chronic Obstructive

Clinical Trials on Spiriva (tiotropium bromide) inhalation capsules

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Canada

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations